L
LivaNova PLC (LIVN)
NMS – Real Time Price. Currency in USD
80.87
+2.29 (2.91%)
Market open: Aug 12, 2026, 11:30 AM EDT
78.58
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
80.87
+2.29 (2.91%)
Market open: Aug 12, 2026, 11:30 AM EDT
78.58
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
| Name | Position |
|---|---|
| Briana Gotlin | Vice President of Investor Relations |
| Deanna Wilke | Vice President of Corporate Communications |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer |
| Mr. Vladimir A. Makatsaria | CEO & Director |
| Ms. Lindsey Little | VP & Chief Accounting Officer |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer |
| Ms. Sarah K. Mohr | VP of Legal & Company Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-08-05 | IRANNOTICE | livn-2026630xirannotice.htm |
| 2026-08-05 | 10-Q | livn-20260630.htm |
| 2026-06-11 | 8-K | livn-20260610.htm |
| 2026-05-29 | SD | a2025conflictmineralsrepor.htm |
| 2026-05-06 | IRANNOTICE | livn-2026331xirannotice.htm |
| 2026-05-06 | 8-K | livn-20260506.htm |
| 2026-05-06 | 10-Q | livn-20260331.htm |
| 2026-04-29 | DEFA14A | tm261392d4_defa14a.htm |
| 2026-04-29 | DEF 14A | tm261392-2_def14a.htm |
| 2026-04-29 | ARS | tm261895d1_ars.pdf |